We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




HIV Viral Load Test Targets Two HIV-1 Genome Regions

By LabMedica International staff writers
Posted on 11 Jul 2012
A new Human Immunodeficiency virus (HIV) viral load test will be commercially available in the US later this year. More...
It targets two highly conserved regions of the HIV-1 genome and avoids any regions which are current drug targets, thus providing increased reliability as compared to other single target assays should a mutation occur.

The COBAS TaqMan HIV-1 Test, v2.0 utilizes the US Food and Drug Administration (FDA; Silver Spring, MD, USA)-approved High Pure System Viral Nucleic Acid Kit for manual specimen preparation and the COBAS TaqMan 48 Analyzer for automated amplification and detection.

Despite the rapidly growing genetic diversity of HIV-1, Roche's (Basel, Switzerland) dual-target approach for HIV viral load testing ensures enhanced reliability of results and increased confidence in assessing viral loads. The test has been approved by the United States FDA.

Since Roche first introduced this innovative dual-target approach for monitoring HIV-1 patients on antiretroviral therapy in 2008, over eight million tests have been performed worldwide on Roche's fully automated real-time PCR platforms.

An estimated 1.2 million persons were living with HIV infection in the United States at the end of 2010. Of those, 20% had undiagnosed HIV infections. Highly active antiretroviral treatment (HAART) and viral load tests that determine the amount of circulating HIV have contributed to a profound increase in life expectancy for people living with HIV.

The test was described in March 2012 and accessed June 18, 2012, in the journal Lancet

Related Links:

US Food and Drug Administration
Roche




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.